Opis działalności
Novavax, Inc. is an American biotechnology company headquartered in Gaithersburg, Maryland. Their mission is to address serious infectious diseases globally through the discovery and development of innovative vaccines. They focus on creating life-saving vaccines using solid science that has been tested through decades of research. Prior to 2020, Novavax scientists developed experimental vaccines for influenza, respiratory syncytial virus (RSV), Ebola, and other emerging infectious diseases. The company engages in the discovery, development, and commercialization of recombinant vaccines
Zarząd & Rada nadzorcza
| CEO |
| John C. Jacobs |
| Zarząd |
| Jim Kelly, John J. Trizzino, Mark Casey, Rick Crowley, Elaine O’Hara, Silvia Taylor, Ian Watkins, Troy Morgan, Robert Walker |
| Rada nadzorcza |
| James F. Young, Gregg Alton, Richard Douglas, Rachel King, Margaret G. McGlynn, David Mott, Rick Rodgers |
Dane firmy
| Nazwa: |
Novavax Inc. |
| Adres: |
21 Firstfield Rd,Gaithersburg |
| Telefon: |
+1-240-2682000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://global.novavax.com/ |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
Biotechnologia |
| Koniec roku finansowego: |
31.12 |
| Free float: |
94,12% |
| Data IPO: |
05.12.1995 |
Relacje inwestorskie
| Nazwa: |
Erika Schultz |
| Telefon: |
+1-240-268-2022 |
| Fax: |
- |
| E-mail: |
ir@novavax.com
|
